By: Halley Ray
We rely heavily on antibiotics as tools to fight and treat bacterial infections.
But we’re in trouble.
We need new antibiotics to stay ahead of drug-resistant infections, yet the companies developing them often can’t build a sustainable business.
This is the perfect example of a market failure.
Developing a new antibiotic takes years of research and significant investment, but once it reaches patients, we actually want doctors to use it sparingly to slow the development of resistance. That’s the right thing to do for public health.
But it’s the wrong thing to do to attract investors. Achaogen filed for bankruptcy in 2019, less than a year after the FDA approved its antibiotic plazomicin. Melinta Therapeutics also filed for bankruptcy that same year, despite having FDA-approved antibiotics in its portfolio.
We can’t expect companies to continue investing in an area where the market doesn’t reward success.
That's why we support the PASTEUR Act. Its subscription-based model would provide predictable payments for qualifying antibiotics. That means a company's return wouldn’t be tied to the volume of medicines it sells, recognizing that a new antibiotic's value is being there when a patient needs it and when existing options don’t work.
This U.S. Antibiotic Awareness Week, we should push for policies that will ensure the next generation of antibiotics actually gets developed. We can’t afford to lose these tools.